Champions Oncology Inc (CSBR)

[Milburn D]

Things are happening...

Champions Oncology Raises $9.3 Million in a Private Placement

HACKENSACK, N.J., Jan 29, 2013 (GLOBE NEWSWIRE via COMTEX) -- Champions
Oncology, Inc. (OTC:CSBR) ("the Company") announced today the company raised
$9.3 million at a price of $0.50 per share in a private placement to existing
and new investors. No commissions were paid in connection with the private
placement. Joel Ackerman, Champions Oncology CEO, stated, "We are pleased to
have the continued support of our existing shareholders and to announce the
addition of a new high quality investor. These proceeds will allow us to move
forward with developing our technology and building our team."

The lead investors were Battery Ventures IX, L.P., PAR Investment Partners,
L.P., Harris & Harris Group Inc., and members of the Company's management team.

-- Proceeds from the financing will be used to: Grow the TumorGraft bank to
support the current Translational Oncology Solutions business and future
biomarker development efforts,

-- Continue to build out the Senior Management team,

-- Initiate a validation study for the Personalized Oncology Solutions business
and

-- General corporate purposes.

The private placement was comprised of the issuance of 18.6 million shares of
common stock to accredited investors at a price of $0.50 per share, a premium of
16% to today's closing price, pursuant to Regulation D of the Securities Act of
1933, as amended. Gross proceeds to the Company will be $9.3 million. Concurrent
with the closing of the private placement, the Company will issue warrants to
the investors which will entitle the holders to purchase up to 1,860,000
additional shares of common stock at $0.66 per share for a period of five years
following the date of issuance. The Company also granted the investors certain
registration rights with respect to the shares of common stock and shares of
common stock issuable upon exercise of the warrants.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology drugs.
The Company's TumorGraft Technology Platform is a novel approach to
personalizing cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the TumorGrafts in a manner
that preserves the biological characteristics in order to determine the efficacy
of a treatment regimen. The Company uses this technology to offer solutions for
Personalized Oncology Solutions, which guides the development of personalized
treatment plans, and Translational Oncology Solutions, which assists
pharmaceutical and biotechnology companies seeking personalized approaches to
drug development to lower the cost and increase the speed of drug development.

For more information, visit www.championsoncology.com.

This press release may contain "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Oncology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year
ended April 30, 2012 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions Oncology's future results,
levels of activity, performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking statements
after the date of this press release to conform these statements to actual
results or to changes in Champions Oncology's expectations, except as required
by law.



CONTACT: Gary Gemignani

Champions Oncology, Inc.

201-808-8408

[e-mail]



Lauren Kwiecinski

The Trout Group LLC

646-378-2934

[e-mail]

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMTk4MzcjMjM4NzM=




(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-




KEYWORD: HACKENSACK, N.J.

INDUSTRY KEYWORD: Healthcare & Medical Services

SUBJECT CODE: Financing Agreements

Health

BIOTECHNOLOGY

HEALTH